Comments
Intas Pharmaceuticals Ltd on Friday announced the launch of Azadine-O, an oral Azacitidine therapy for Acute Myeloid Leukemia (a type of blood cancer), a first for the Indian market.
Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. It can improve survival by almost 10 months and bridge a long-pending unmet need in cancer therapy, a company statement said.
M B Agarwal, one of India's leading haematologists, commented, "Oral Azacitidine will prove to be extremely useful for AML patients. There was a dire need for this drug. It shall significantly improve survival and quality of life of patients."
In 2014, Intas triggered a paradigm change in the treatment of MDS - myelodysplastic syndrome - with the launch of AZADINE (Injectable Azacitidine).
Azadine-O is yet another progressive breakthrough in the treatment of Acute Myeloid Leukemia.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.